Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: A hoosier oncology group study

Bryan Schneider, Kristen N. Ganjoo, David E. Seitz, Joel Picus, Farid Fata, Cindy Stoner, Cynthia Calley, Patrick Loehrer

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Objective: To determine the response rate, duration of response and survival with weekly gemcitabine plus docetaxel in metastatic or unresectable pancreatic cancer. Methods: Forty patients were enrolled, and 38 patients were evaluable for survival and toxicity. Thirty-seven patients were evaluable for response. Nine patients (24%) had locally advanced disease and 29 (76%) had metastatic disease at the time of enrollment. Median Eastern Cooperative Oncology Group performance status was 1. Patients received gemcitabine 750 mg/m2 i.v. and docetaxel 35 mg/m2 i.v. weekly for 3 out of 4 weeks for a maximum of 6 cycles. Results: Patients received a median of 4 cycles (range 1-6) of chemotherapy. An objective response was obtained in 10 patients (27%) with a median duration of 17 weeks. Median survival was 7 months, and 1-year survival was 19.3%. Eight patients experienced at least one form of grade 4 toxicity and 27 patients experienced at least one type of grade 3 toxicity. Conclusions: The combination of gemcitabine and docetaxel is a well-tolerated regimen with clinical efficacy. The ultimate role of this combination versus single-agent gemcitabine can only be determined by a randomized phase III trial.

Original languageEnglish
Pages (from-to)218-223
Number of pages6
JournalOncology
Volume65
Issue number3
DOIs
StatePublished - 2003

Fingerprint

docetaxel
gemcitabine
Pancreatic Neoplasms
Survival

Keywords

  • Docetaxel
  • Gemcitabine
  • Pancreatic cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer : A hoosier oncology group study. / Schneider, Bryan; Ganjoo, Kristen N.; Seitz, David E.; Picus, Joel; Fata, Farid; Stoner, Cindy; Calley, Cynthia; Loehrer, Patrick.

In: Oncology, Vol. 65, No. 3, 2003, p. 218-223.

Research output: Contribution to journalArticle

Schneider, Bryan ; Ganjoo, Kristen N. ; Seitz, David E. ; Picus, Joel ; Fata, Farid ; Stoner, Cindy ; Calley, Cynthia ; Loehrer, Patrick. / Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer : A hoosier oncology group study. In: Oncology. 2003 ; Vol. 65, No. 3. pp. 218-223.
@article{886bd53a33a241568c3060e45ba181a0,
title = "Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: A hoosier oncology group study",
abstract = "Objective: To determine the response rate, duration of response and survival with weekly gemcitabine plus docetaxel in metastatic or unresectable pancreatic cancer. Methods: Forty patients were enrolled, and 38 patients were evaluable for survival and toxicity. Thirty-seven patients were evaluable for response. Nine patients (24{\%}) had locally advanced disease and 29 (76{\%}) had metastatic disease at the time of enrollment. Median Eastern Cooperative Oncology Group performance status was 1. Patients received gemcitabine 750 mg/m2 i.v. and docetaxel 35 mg/m2 i.v. weekly for 3 out of 4 weeks for a maximum of 6 cycles. Results: Patients received a median of 4 cycles (range 1-6) of chemotherapy. An objective response was obtained in 10 patients (27{\%}) with a median duration of 17 weeks. Median survival was 7 months, and 1-year survival was 19.3{\%}. Eight patients experienced at least one form of grade 4 toxicity and 27 patients experienced at least one type of grade 3 toxicity. Conclusions: The combination of gemcitabine and docetaxel is a well-tolerated regimen with clinical efficacy. The ultimate role of this combination versus single-agent gemcitabine can only be determined by a randomized phase III trial.",
keywords = "Docetaxel, Gemcitabine, Pancreatic cancer",
author = "Bryan Schneider and Ganjoo, {Kristen N.} and Seitz, {David E.} and Joel Picus and Farid Fata and Cindy Stoner and Cynthia Calley and Patrick Loehrer",
year = "2003",
doi = "10.1159/000074474",
language = "English",
volume = "65",
pages = "218--223",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "3",

}

TY - JOUR

T1 - Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer

T2 - A hoosier oncology group study

AU - Schneider, Bryan

AU - Ganjoo, Kristen N.

AU - Seitz, David E.

AU - Picus, Joel

AU - Fata, Farid

AU - Stoner, Cindy

AU - Calley, Cynthia

AU - Loehrer, Patrick

PY - 2003

Y1 - 2003

N2 - Objective: To determine the response rate, duration of response and survival with weekly gemcitabine plus docetaxel in metastatic or unresectable pancreatic cancer. Methods: Forty patients were enrolled, and 38 patients were evaluable for survival and toxicity. Thirty-seven patients were evaluable for response. Nine patients (24%) had locally advanced disease and 29 (76%) had metastatic disease at the time of enrollment. Median Eastern Cooperative Oncology Group performance status was 1. Patients received gemcitabine 750 mg/m2 i.v. and docetaxel 35 mg/m2 i.v. weekly for 3 out of 4 weeks for a maximum of 6 cycles. Results: Patients received a median of 4 cycles (range 1-6) of chemotherapy. An objective response was obtained in 10 patients (27%) with a median duration of 17 weeks. Median survival was 7 months, and 1-year survival was 19.3%. Eight patients experienced at least one form of grade 4 toxicity and 27 patients experienced at least one type of grade 3 toxicity. Conclusions: The combination of gemcitabine and docetaxel is a well-tolerated regimen with clinical efficacy. The ultimate role of this combination versus single-agent gemcitabine can only be determined by a randomized phase III trial.

AB - Objective: To determine the response rate, duration of response and survival with weekly gemcitabine plus docetaxel in metastatic or unresectable pancreatic cancer. Methods: Forty patients were enrolled, and 38 patients were evaluable for survival and toxicity. Thirty-seven patients were evaluable for response. Nine patients (24%) had locally advanced disease and 29 (76%) had metastatic disease at the time of enrollment. Median Eastern Cooperative Oncology Group performance status was 1. Patients received gemcitabine 750 mg/m2 i.v. and docetaxel 35 mg/m2 i.v. weekly for 3 out of 4 weeks for a maximum of 6 cycles. Results: Patients received a median of 4 cycles (range 1-6) of chemotherapy. An objective response was obtained in 10 patients (27%) with a median duration of 17 weeks. Median survival was 7 months, and 1-year survival was 19.3%. Eight patients experienced at least one form of grade 4 toxicity and 27 patients experienced at least one type of grade 3 toxicity. Conclusions: The combination of gemcitabine and docetaxel is a well-tolerated regimen with clinical efficacy. The ultimate role of this combination versus single-agent gemcitabine can only be determined by a randomized phase III trial.

KW - Docetaxel

KW - Gemcitabine

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=0344305656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344305656&partnerID=8YFLogxK

U2 - 10.1159/000074474

DO - 10.1159/000074474

M3 - Article

C2 - 14657595

AN - SCOPUS:0344305656

VL - 65

SP - 218

EP - 223

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 3

ER -